Posterior reversible encephalopathy syndrome in an HIV-infected patient on antiretroviral treatment: what is the risk factor? by Birner, Barbara et al.
1Birner B, et al. BMJ Case Rep 2018. doi:10.1136/bcr-2017-221998
Summary
Posterior reversible encephalopathy syndrome (PRES) is 
a rare but well-described syndrome associated with a 
high morbidity and a substantial mortality. We present 
an illustrative case of an HIV-infected but virologically 
suppressed patient who complained of visual impairment 
accompanied by severe headache and epileptic seizures. 
The cerebral CT scan and the follow-up cranial MRI 
confirmed the diagnosis of PRES. Unlike the cases of HIV-
infected patients with PRES published so far, our patient 
suffered neither from advanced immunodeficiency nor 
from opportunistic infection or from any other evident 
predisposing factor. This case highlights that the absence 
of classical risk factors does not exclude the diagnosis 
of PRES. We discuss the hypothesis that in accordance 
with the new pathophysiological theory, persistent HIV-
associated cerebrovascular reactivity in combination with 
endothelial dysfunction may represent an undetected risk 
factor for the development of PRES in virologically and 
immunologically stable patients.
Background
Posterior reversible encephalopathy syndrome 
(PRES), also known as reversible posterior leuko-
encephalopathy syndrome, is a spontaneously 
resolving syndrome characterised by the radio-
graphic finding of a bilateral subcortical vasogenic 
oedema.1 The vasogenic oedema of the brain—
predominantly involving the posterior parietal 
and occipital lobes2 3—is caused by an autoregu-
latory dysfunction of brain vessels. This leads to 
arteriolar dilatation and hyperperfusion together 
with hydrostatic leakage and interstitial fluid accu-
mulation in cortex and subcortical white matter.4 
Frank infarction with cytotoxic oedema is rarely 
described. However, primary endothelial dysfunc-
tion may also lead to a release of inflammatory 
mediators with weakening of the brain vessels’ tight 
junctions, followed by oedema.5 Many patients 
with PRES do not show typical risk factors such 
as hypertension, eclampsia, immunosuppression 
or an inflammatory state.6–10 We present the rare 
case of a female HIV-infected patient with a long 
history of antiretroviral treatment (ART), an unde-
tectable HIV viral load and a high CD4 cell count. 
No classical risk factors for PRES were present. In 
contrast to the cases of HIV-infected patients with 
PRES published so far,11–15 our patient suffered 
neither from advanced immunodeficiency nor from 
opportunistic infection. However, it is conceivable 
that the impaired cerebrovascular reactivity, which 
persists even in treated and virally suppressed HIV₋
infected individuals, and the persistent immune 
activation in these patients may represent an unde-
tected risk factor for the development of PRES.16 17 
caSe preSentation
A 51-year-old woman infected with HIV, who had 
been on first-line ART (zidovudine, lamivudine and 
abacavir) for 16 years, was admitted to hospital 
with fever, neck stiffness and altered mental status. 
She had a Glasgow Coma Scale  of 12 and was 
febrile (38.4°C) on admission. Her blood pressure 
(114/74 mm Hg), pulse (92 beats/min) and respira-
tory rate (17 breaths/min) were within the normal 
range. Besides the HIV infection, she had a history 
of chronic obstructive pulmonary disease (treated 
with inhaled corticosteroids), an idiopathic pulmo-
nary embolism 3 months before admission (treated 
with rivaroxaban) and previous history of intrave-
nous drug abuse. For the past 16 years, the patient’s 
HIV status had been clinically and immunologically 
stable with no evidence of opportunistic diseases.
The results of the laboratory tests at the time of 
her admission were: CD4 count 401 cells/µL, HIV 
viral load below the level of detection (<20 copies/
mL), as it had been in the years before. The patient 
had a normal leucocyte count (7300x10^9/L), 
slightly elevated liver enzymes (aspartate amino-
transferase  152 U/L, alanine aminotransferase 
99 U/L) and inflammation parameters (C reactive 
protein, 22 mg/L) and a creatinine level of 138 
μmol/L. Blood cultures remained sterile.
Initially, we suspected meningoencephalitis and 
initiated empirical treatment with ceftriaxone, 
amoxicillin, vancomycin and acyclovir in combina-
tion with systemic corticosteroids.
The patient recovered completely within 2 days.
After stopping the oral anticoagulation, a lumbar 
puncture as a diagnosis of exclusion was performed 
3 days after admission: no elevation of the cell 
count (1.0 leucocytesx10^9/L), the protein level 
(0.18 g/L) or the lactate level was detected. There-
fore, the antimicrobial treatment was stopped.
However, 4 days after admission, the patient 
reported bilateral visual impairment accompanied 
by severe headache and subsequently suffered 
a tonic–clonic epileptic seizure. The ophthal-
mological examination revealed a bitemporal 
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hemianopsia, visual agnosia, especially prosopagnosia, but no 
abnormal findings on a split lamp examination. Blood pressure 
was 200/120 mm Hg during this episode.
A contrast-enhanced cerebral CT scan revealed bilateral 
cortical and subcortical hypodense lesions in the territories of 
the posterior circulation (figure 1).
T2-weighted (T2w) and fluid-attenuated inversion recovery 
(FLAIR) magnetic resonance imaging (MRI) of the brain showed 
patchy hyperintense signal alterations—asymmetric bilateral 
cortical and subcortical parieto-occipital—with associated 
diffusion restriction (figures 2 and 3). Additionally, infratento-
rial large asymmetric patchy T2w and FLAIR hyperintensities 
were noted in both cerebellar hemispheres. The lesions showed 
neither contrast medium uptake nor blooming artefacts (eg, 
haemorrhage or calcifications).
The electroencephalogram reinforced these findings, showing 
moderate decelerating foci in the left hemisphere with lateralised 
periodic discharges and bi-occipital spike–wave complexes with 
no signs of convulsive status epilepticus.
Echocardiography and ECG performed 1 month before 
admission had been normal and showed no signs of hypertensive 
cardiomyopathy.
outcome and follow-up
After initiation of antiepileptic and antihypertensive treat-
ment with levetiracetam and amlodipine, respectively, the 
patient's neurological symptoms improved immediately. She was 
discharged after 8 days with no further neurological symptoms 
and a normal creatinine level. Antihypertensive therapy was 
stopped after a few days because of hypotonia. The patient 
remained asymptomatic and normotensive during a follow-up 
period of 1 year.
diScuSSion
PRES is characterised by headache, nausea, alteration of 
consciousness, seizures and visual disturbance. Brain imaging 
(CT and/or MRI) reveals characteristic white-matter vasogenic 
oedema predominantly affecting the parietal and occipital 
lobes.2 3
Two main hypotheses about the pathophysiology of PRES 
have been proposed. The more widely held theory suggests a 
breakdown of the autoregulatory system due to uncontrolled 
hypertension and subsequent hyperperfusion. The second 
theory is that activation of the autoregulatory system is caused 
by hypertension, and this results in vasoconstriction of brain 
vessels followed by hypoperfusion, brain ischaemia and subse-
quent fluid leakage.4 However, a certain proportion of patients 
with PRES do not have hypertension. Therefore, a third, more 
recent, theory about the pathophysiology of PRES, focusing on 
inflammatory processes, has gained attention. Activation of the 
immune system as well as endothelial dysfunction can lead to a 
release of leucocytes and tumour necrosis factor alpha. This, in 
turn, stimulates the expression of vascular endothelial growth 
factor. By this means, the tight junctions of the brain vessels are 
weakened and brain oedema ensues. According to this theory, 
hypertension seems to be an ancillary phenomenon.1 5
figure 1 The axial native CT scan of the brain 4 days after 
hospitalisation showed relatively symmetrical bi-occipital patchy 
hypodense areas in the territories of the posterior circulation, cortical 
and subcortical, predominantly right sided.
figure 2 In line with the CT scan, the MRI of the brain (axial FLAIR) 
revealed symmetrical, T2w and FLAIR patchy hyperintense signal 
alterations, asymmetric bilateral cortical and subcortical parieto-
occipital. FLAIR, fluid-attenuated inversion recovery; T2w, T2 weighted.
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However, case reports and case series suggest that PRES is 
mostly associated with arterial hypertension, especially in the 
presence of (pre-)eclampsia, autoimmune disease, hypomag-
nesaemia, end-stage kidney disease or non-steroid immuno-
suppressive therapy.6–10 Classical risk factors for PRES were 
absent in our patient. Uncontrolled hypertension had never 
been documented previously or in the follow-up period and 
was only present during the symptomatic phase, suggesting that 
hypertension was an attendant phenomenon or a consequence 
of increased sympathetic activation, the tonic–clonic epileptic 
seizure and the PRES-induced brain oedema. However, as the 
patient was febrile at admission, we cannot exclude the possi-
bility that an inflammatory syndrome may have played a role in 
the development of the PRES. Cases of PRES caused by systemic 
corticosteroids have also been described.18 19
Since 2002, PRES in HIV-positive patients has been described 
in a few case reports. Risk factors in the HIV-positive population 
were heterogeneous and included uncontrolled and untreated 
HIV infection,20 opportunistic infections in patients on tubercu-
losis and ART cotherapy,15 21 22arterial hypertension, end-stage 
renal disease,14 23 and thrombotic thrombocytopenic purpura.24 
Most of the HIV-infected patients described in these case reports 
had advanced immunodeficiency with a CD4 count varying from 
28 to 290/μL, and few of them were patients on ART with low 
or undetectable HIV viral load.15 The diversity of the published 
cases makes it impossible to determine the exact role of HIV or 
ART in the development of PRES and does not allow any defin-
itive conclusion as to its pathogenesis or causality.
IRIS, an immune reconstitution inflammatory syndrome 
involving neurological structures, was excluded as a cause 
of PRES in our immunovirologically stable patient. PRES is 
not a manifestation of IRIS, which develops in HIV-infected 
patients with pre-existing infection at initiation of ART with 
rapid improvement of immune function. It remains unclear if 
long-term exposure to the combination ART with three nucle-
oside reverse transcriptase inhibitors exclusively, antiretroviral 
agents known to induce mitochondrial damage in endothelial 
cells, may be a cofactor contributing to endothelial dysfunc-
tion and PRES.
Although the endothelial dysfunction improves after the initi-
ation of ART, the cerebrovascular reactivity and the systemic 
inflammation do not revert to normal levels even if the HIV viral 
loads are undetectable in patients on ART.16 17 25 It is conceivable 
that these factors predisposed our patient, who had no other 
obvious risk factors, to develop PRES.
In summary, our case highlights how the identification 
of classical trigger factors for the development of PRES in 
HIV-positive patients may be difficult. Based on pathophys-
iological considerations we hypothesise that HIV infection 
may play a role in the pathogenesis of PRES even in virologi-
cally suppressed individuals. To conclusively evaluate the role 
of HIV in the pathogenesis of PRES, epidemiological studies 
would inevitably be needed.
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figure 3 The MRI of the brain (axial FLAIR) demonstrated, in addition 
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learning points
 ► Posterior reversible encephalopathy syndrome (PRES) is a rare 
syndrome characterised by the development of a bilateral 
subcortical vasogenic cerebral oedema, which mainly affects 
the occipital lobe.
 ► PRES can occur in HIV-infected patients who have no other 
predisposing factors and in the absence of active virus 
replication or opportunistic infection.
 ► Pathophysiological considerations may raise the hypothesis 
that HIV infection could be a previously unknown risk factor 
for PRES.
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